2nd June 2011
A new gel injection used to treat people with severe faecal incontinence has been approved by the Food and Drug Association (FDA) in America.
Solesta is to be used by patients who have not had success with other more common therapies, such as fibre therapy, a modified diet or traditional medication.
It is injected into the layer of tissue just beneath the anal lining, and works by growing the surrounding tissue to narrow the opening of the anus and give patients more ability to control muscles.
Researchers tested the injection on 206 people who suffered with loss of bowel control. Over half of the group experienced a 50 per cent drop in the number of episodes where they experienced faecal incontinence. There were side effects, however, with the most common being bleeding and pain at the injection site, anal tissue inflammation and infection.
Christy Foreman, of the FDA's Office of Device Evaluation, said: "Faecal incontinence is difficult to treat. This approval provides a minimally invasive treatment option for patients with faecal incontinence that does not respond to conservative therapies."
The most common cause of faecal incontinence is damage to muscles in the anus, according to the Bladder and Bowel Foundation. It affects around two per cent of the population.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare